Said Dermime received his Ph.D. degree in immunology from Salford University, Manchester, UK in 1992. He joined the National Cancer Institute, Milan, Italy for a period of 2 years as Postdoctoral Fellow. He then joined the NHLBI, NIH, Bethesda, Md USA, for a period of 2 years under an NIH Fogarty International Award. He then joined PPL Therapeutics Ltd, London, UK, and COBRA Therapeutics Ltd., UK, to gain industrial experience. He was appointed after this period at the Paterson Institute for Cancer Research, Manchester, UK, as a lymphoma-cancer-vaccine Team Leader for 4 years. Subsequently, he established and led the Tumor Immunology Section at King Faisal Specialist Hospital & Research Centre, Riyadh, KSA, for a period of 6 years as a Senior Scientist. Recently, he joined the Dasman Institute in Kuwait to establish and lead the Department of Biomedical Research and to head the Immunology & Innovative Cell Therapy Unit. He is a member of several international scientific societies such as the British Society of Immunology, the American Association of Immunology, and the European Association for Cancer Research. He supervised several Ph.D. and Master students and received several research grants from different organizations such as Christie Hospital Endowment funds (United Kingdom), ASTF (United Arab Emirates), CAKST (Saudi Arabia), and KFAS (Kuwait). His is an expert in tumor immunology and immune regulation. He has over 20 years experience in cellular immunology, tumor models, cancer vaccines, and T cell cloning and characterization. He published over 32 peer-reviewed articles in which some of them were published in high-impact factor journal such as Blood, Cancer Research, and Journal of Immunology (http://www.iamscientist.com/people/sdermime2010).
Biography Updated on 14 April 2011